CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 168 enrolled
Drug / intervention
placebo +5 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01528605
NCT01528605N/ACompleted
CompareCT.gov

The Effects of Lutein and Zeaxanthin Supplementations on Early Age-related Macular Degeneration

Peking University·interventional·Posted Feb 8, 2012·Updated Aug 29, 2014

In Brief

A clinical study evaluating placebo, low lutein, and 4 other interventions for Age-related Macular Degeneration. Completed, enrolled 168 participants across 1 site.

Detailed Summary

This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 8, 2012
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.4 years ago

Interventions

placebodietary

Placebo, one gelatine capsule containing starch per day, for 96 weeks

low luteindietary

one gelatine capsule containing 10mg lutein per day, for 96 weeks

high luteindietary

one gelatine capsule containing 20mg lutein per day, for 96 weeks

lutein plus zeaxanthindietary

one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks

high zeaxanthindietary

one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks

zeaxanthin plus luteindietary

one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks